| 2026-08-12 | Press release | Press Release |
| 2026-08-10 | Press release | Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026 |
| 2026-08-03 | Press release | CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA® |
| 2026-06-26 | Press release | Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA |
| 2026-06-18 | Press release | Omeros Announces Webcast Details for Annual Meeting of Shareholders |
| 2026-06-15 | Press release | Download , Omeros Announces Webcast Details for Annual Meeting of Shareholders, June 15, 2026, (opens in new window) |
| 2026-05-13 | Press release | Omeros Corporation Reports First Quarter 2026 Financial Results |
| 2026-05-13 | Press release | Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026 |
| 2026-05-13 | Press release | Press Release
of Q1 2026, PDF file, (opens in new window) |
| 2026-05-11 | Press release | Download , Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026, May 11, 2026, (opens in new w |
| 2026-04-30 | Proxy statement | Proxy Statement of 2025 Annual Report, PDF file, (opens in new window) |
| 2026-04-16 | Press release | CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug) |
| 2026-03-31 | Press release | Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results |
| 2026-03-26 | Press release | Download , Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026, March 2 |
| 2026-03-26 | Press release | Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026 |
| 2026-03-21 | Press release | Download , Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment, March 21, 2026 |
| 2026-03-21 | Press release | Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment |
| 2026-02-17 | Press release | Download , Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program, February 17, 2026, (opens in new wind |
| 2026-02-17 | Press release | Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program |
| 2026-01-27 | Press release | Download , Omeros Announces First Commercial Sales of YARTEMLEA®, January 27, 2026, (opens in new window) |
| 2026-01-27 | Press release | Omeros Announces First Commercial Sales of YARTEMLEA® |
| 2025-12-26 | Press release | Omeros Announces New Date for YARTEMLEA® Approval Conference Call |
| 2025-12-24 | Press release | FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA |
| 2025-12-01 | Press release | Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stag |
| 2025-11-13 | Press release | Omeros Corporation Reports Third Quarter 2025 Financial Results |
| 2025-11-11 | Press release | Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025 |
| 2025-10-16 | Press release | Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Ma |
| 2025-10-15 | Press release | Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zalten |
| 2025-09-02 | Press release | Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global |
| 2025-08-14 | Press release | Omeros Corporation Reports Second Quarter 2025 Financial Results |
| 2025-08-11 | Press release | Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025 |
| 2025-07-25 | Press release | Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering |
| 2025-06-27 | Press release | Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA- |
| 2025-06-24 | Press release | Omeros Announces Webcast Details for Annual Meeting of Shareholders |
| 2025-05-30 | Annual report | Annual Report of 2024 Annual Report, PDF file, (opens in new window) |
| 2025-05-15 | Press release | Omeros Corporation Reports First Quarter 2025 Financial Results |
| 2025-05-12 | Press release | Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025 |
| 2025-05-12 | Press release | Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026 |
| 2025-05-06 | Press release | FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiop |
| 2025-04-10 | Press release | Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML C |